All In Biotech

Drug Trial Radar · NCT06200376

A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer

A Clinical Study of Safety and Efficacy of T3011 Administered Via Intraperitoneal Injection as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Jan 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

10

Planned (sponsor's estimate)

Start

Sep 28, 2023

Primary completion

Dec 2024

Study completion Dec 2024

Sponsor

Lead sponsor
West China HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open, single-arm, investigator-initiated clinical study to evaluate the safety and efficacy of intraperitoneal administration of T3011 at different doses in the treatment of malignant ascites induced by advanced colorectal cancer.

Conditions

  • Malignant Ascites

Interventions

  • T3011Drug

    T3011 will be administered intraperitoneally twice a week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventTime frame: 28 days after EOT

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.